The multifunctional nature of Alzheimer's disease calls for MTDLs (multitarget-directed
ligands) to act on different components of the pathology, like the cholinergic dysfunction and …

The structure of Torpedo californica acetylcholinesterase is examined in complex with
several inhibitors that are either in use or under development for treating Alzheimer's …

Human acetylcholinesterase (AChE) is a significant target for therapeutic drugs. Here we
present high resolution crystal structures of human AChE, alone and in complexes with drug …

Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) hydrolyze the
neurotransmitter acetylcholine and, thereby, function as coregulators of cholinergic …

Huprine X is a novel acetylcholinesterase (AChE) inhibitor, with one of the highest affinities
reported for a reversible inhibitor. It is a synthetic hybrid that contains the 4-aminoquinoline …

Inhibitors of the enzyme acetylcholinesterase (AChE) slow and sometimes reverse the
cognitive decline experienced by individuals with Alzheimer's disease. Huperzine A, a …

Acetylcholinesterase is a critical enzyme that regulates neurotransmission by degrading the
neurotransmitter acetylcholine in synapses of the nervous system. It is an important target for …

A family of huprine–tacrine heterodimers has been developed to simultaneously block the
active and peripheral sites of acetylcholinesterase (AChE). Their dual site binding for AChE …

Tacrine-based AChE and BuChE inhibitors were designed by investigating the topology of
the active site gorge of the two enzymes. The homobivalent ligands characterized by a …

Recently advances in understanding the molecular basis of Alzheimer's disease have led to
the consideration of the relationship between cholinergic inhibitors and amyloid deposition …